...
CBUSMICRO

Cibus, Inc.

HealthcareBiotechnology
$3.33
$0.00(-6.72%)
52W$1.09
$3.80
FinancialsValuationvs RPRX
Updated Mar 5, 12:00 AM
RSI67
RS Rating96/99
Beta1.89
Volatility107%
F-Score4/9
Mkt Cap$99M
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Cibus, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 96), indicating clear outperformance against the broad market. Earnings growth of 94% provides fundamental context to the price action. However, price is extended 46% above the 50-day line, increasing the risk of a mean reversion.

Relative Strength
96
out of 99
Market Leader
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
1.89
vs S&P 500
HIGH BETA
52W Position
83%
from 52W low
Near High
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$2.28
50 SMA > 100 SMA$1.87
100 SMA > 150 SMA$1.71
150 SMA > 200 SMA$1.76

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$2.89+15.09%ABOVE
50 SMA$2.28+46.35%ABOVE
100 SMA$1.87+78.15%ABOVE
150 SMA$1.71+94.95%ABOVE
200 SMA$1.76+89.34%ABOVE

Price Performance

1D-6.7%
1W-5.4%
1M+48.7%
3M+103.0%
6M+160.2%
YTD+77.1%
1Y+49.3%
3Y-46.5%
52-Week Trading Range83% from low
$3.33
52W Low$1.09
52W High$3.80

Technical Indicators

RSI (14)BULLISH
67.0
305070
VCP ScoreCOOL
4/10
Base depth: 70.3%

Risk Profile

Beta
1.89
52W Vol
107%
ATR
$0.30
Max DD (1Y)
-65%

Volume Analysis

Today
647.8K
50D Avg
400.5K
Vol Ratio
1.62x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24+93%
$-0.87
Q1'25-80%
$-2.02
Q2'25+46%
$-0.61
Q3'25+94%
$-0.44
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:-10.19%
3 Years:-45.26%
TTM:-8.64%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+82.02%

Stock Price CAGR

10 Years:-40.13%
5 Years:-60.96%
3 Years:-46.50%
1 Year:+49.33%

Return on Equity

10Y Avg:-88.3%
5Y Avg:-126.6%
3Y Avg:-142.8%
Last Year:-228.5%

Key Metrics

Market Cap$99M
Gross Margin1.0%
Net Margin-59.0%
Piotroski F-Score4/9

More CBUS Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

CBUS vs RPRXRPRXLGNDINVABTX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 96 meansCBUS outperformed 96% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.89 means 89% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 4/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 4/10 with COOL status.

Frequently Asked Questions

Is CBUS in an uptrend right now?

CBUS has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is CBUS overbought or oversold?

CBUS's RSI (14) is 67. The stock is in neutral territory, neither overbought nor oversold.

Is CBUS outperforming the market?

CBUS has a Relative Strength (RS) Rating of 96 out of 99. Yes, CBUS is a market leader, outperforming 96% of all stocks over the past 12 months.

Where is CBUS in its 52-week range?

CBUS is trading at $3.33, which is 88% of its 52-week high ($3.80) and 83% above its 52-week low ($1.09).

How volatile is CBUS?

CBUS has a Beta of 1.89 and 52-week volatility of 107%. It's more volatile than the S&P 500 - expect bigger swings.